Trinity Biotech Plc Stock Performance
| TRIB Stock | USD 0.67 0.03 4.29% |
The entity has a beta of 1.41, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Trinity Biotech will likely underperform. At this point, Trinity Biotech plc has a negative expected return of -0.14%. Please make sure to validate Trinity Biotech's value at risk and the relationship between the accumulation distribution and relative strength index , to decide if Trinity Biotech plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Trinity Biotech plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 3.7 M | |
| Total Cashflows From Investing Activities | -23 M |
Trinity Biotech Relative Risk vs. Return Landscape
If you would invest 79.00 in Trinity Biotech plc on May 1, 2025 and sell it today you would lose (12.00) from holding Trinity Biotech plc or give up 15.19% of portfolio value over 90 days. Trinity Biotech plc is currently does not generate positive expected returns and assumes 5.3661% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Trinity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trinity Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trinity Biotech plc, and traders can use it to determine the average amount a Trinity Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0256
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRIB |
Estimated Market Risk
| 5.37 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Trinity Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trinity Biotech by adding Trinity Biotech to a well-diversified portfolio.
Trinity Biotech Fundamentals Growth
Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 108.14 M | ||||
| Shares Outstanding | 18.63 M | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 61.55 M | ||||
| EBITDA | (16.91 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 100.76 M | ||||
| Book Value Per Share | (1.96) X | ||||
| Cash Flow From Operations | (4.19 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Total Asset | 103.29 M | ||||
| Retained Earnings | (79.12 M) | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
About Trinity Biotech Performance
By analyzing Trinity Biotech's fundamental ratios, stakeholders can gain valuable insights into Trinity Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trinity Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trinity Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Bio operates under Pharmaceuticals And Biosciences classification in the United States and is traded on NASDAQ Exchange. It employs 477 people.Things to note about Trinity Biotech plc performance evaluation
Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trinity Biotech plc generated a negative expected return over the last 90 days | |
| Trinity Biotech plc has high historical volatility and very poor performance | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |